Evaluation of immunotherapy efficacy in gynecologic cancer
Various immunotherapies have demonstrated remarkable success over the past few decades, and have been approved for the treatment of different cancer types. However, patient responses to immunotherapy are variable, and approximately 50% of cases are refractory to these agents. Tumor biomarker-based s...
Main Authors: | Genyi Jiang, Qianhua Wu, Bilan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1061761/full |
Similar Items
-
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions
by: Rita T. Lawlor, et al.
Published: (2021-06-01) -
Predicting immunotherapy outcomes in patients with MSI tumors using NLR and CT global tumor volume
by: Younes Belkouchi, et al.
Published: (2022-10-01) -
Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond
by: Robin Park, et al.
Published: (2021-04-01) -
The Immune Microenvironment in Penile Cancer and Rationale for Immunotherapy
by: Mohamed E. Ahmed, et al.
Published: (2020-10-01) -
Possible Biomarkers for Cancer Immunotherapy
by: Takehiro Otoshi, et al.
Published: (2019-07-01)